Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management
Q Zhang, L Tang, Y Zhou, W He, W Li - Frontiers in immunology, 2021 - frontiersin.org
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …
[HTML][HTML] Corticosteroid-resistant immune-related adverse events: a systematic review
E Daetwyler, T Wallrabenstein, D König… - … for immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for
various cancer types. Although the treatment is effective, ICI can overstimulate the patient's …
various cancer types. Although the treatment is effective, ICI can overstimulate the patient's …
[HTML][HTML] Steroid-refractory PD-(L) 1 pneumonitis: incidence, clinical features, treatment, and outcomes
Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve
with corticosteroids and requires additional immunosuppression is termed steroid-refractory …
with corticosteroids and requires additional immunosuppression is termed steroid-refractory …
[HTML][HTML] Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
Background Pneumonitis related to immune checkpoint blockade is uncommon but can be
severe, fatal or chronic. Steroids are first-line treatment, however, some patients are …
severe, fatal or chronic. Steroids are first-line treatment, however, some patients are …
Pulmonary toxicities associated with the use of immune checkpoint inhibitors: An update from the immuno-oncology subgroup of the neutropenia, infection & …
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting …
treatment, with agents such as nivolumab, pembrolizumab, and cemiplimab targeting …
Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond
Abstract Purpose of Review Checkpoint inhibitor pneumonitis (CIP) is a toxicity of immune
checkpoint blockade (ICB) that can be highly morbid and at times fatal. Here, we review the …
checkpoint blockade (ICB) that can be highly morbid and at times fatal. Here, we review the …
Insights into potential pathogenesis and treatment options for immune-checkpoint inhibitor-related pneumonitis
H Ando, K Suzuki, T Yanagihara - Biomedicines, 2021 - mdpi.com
Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4),
programmed cell death-1 (PD-1), and programmed cell death-1-ligand 1 (PD-L1) have …
programmed cell death-1 (PD-1), and programmed cell death-1-ligand 1 (PD-L1) have …
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases
Y Liu, L Jiang - Journal of Oncology Pharmacy Practice, 2021 - journals.sagepub.com
Introduction Immune checkpoint inhibitors (ICI) has demonstrated significant clinical benefit
in advanced cancer. Despite favorable benefits, the use of ICI is accompanied by various …
in advanced cancer. Despite favorable benefits, the use of ICI is accompanied by various …